Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice
SARS-CoV-2 continues to circulate in the human population necessitating regular booster immunization for its long-term control. Ideally, vaccines should ideally not only protect against symptomatic disease, but also prevent transmission via asymptomatic shedding and cover existing and future variant...
Сохранить в:
Главные авторы: | , , , , , , , , , , , , , |
---|---|
Формат: | Статья |
Язык: | английский |
Опубликовано: |
Philipps-Universität Marburg
2023
|
Предметы: | |
Online-ссылка: | PDF-полный текст |
Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|
No abstracts were found for this record.